Access cutting-edge down syndrome-associated alzheimer's disease (ds-ad) treatment through this phase 2 clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Indianapolis location
Preparing your pre-screening questions…
Access down syndrome-associated alzheimer's disease (ds-ad) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related down syndrome-associated alzheimer's disease (ds-ad) treatment provided free
Check if you qualify for this down syndrome-associated alzheimer's disease (ds-ad) clinical trial in Indianapolis, IN
No-Cost Study Care
Local to Indianapolis
Convenient for IN residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
The purpose of the study is to evaluate the effect of mivelsiran in adult participants with early-stage DS-AD and to characterize the safety, tolerability, and pharmacodynamics (PD) of mivelsiran. The study will be conducted over 2 periods: a 24-month double-blind period and an optional 12-month open-label treatment extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 39 months.
Sponsor: Alnylam Pharmaceuticals
Yes, this clinical trial (NCT07636811) has an active research site in Indianapolis, IN that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for down syndrome-associated alzheimer's disease (ds-ad) treatment options in Indianapolis, IN, this clinical trial (NCT07636811) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Indianapolis research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced down syndrome-associated alzheimer's disease (ds-ad) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all down syndrome-associated alzheimer's disease (ds-ad) clinical trials near you to find additional studies recruiting in your area.
See all alzheimers disease clinical trials recruiting in Indianapolis — not just this study.
Browse Alzheimers Disease Trials in Indianapolis →